Set a fixed weekly injection day, expect appetite change before scale change, front-load protein and water, and treat the 48 hours after each dose as the window where food choices matter most.
Before your first dose
Confirm the concentration on your vial and the volume that equals 2.5 mg — write it down. Photograph the label. Set a weekly recurring reminder for your chosen injection day, ideally an evening before a lighter next day. Take a starting weight and waist measurement, and a photo you will not look at for two months.
Week one
Expect appetite quieting rather than dramatic loss. Mild nausea, fatigue or a metallic taste are common. Eat smaller and more often. Drink deliberately — thirst signaling gets quieter along with hunger, and dehydration is behind a lot of the fatigue and headache people attribute to the drug.
Weeks two to four
Establish the routines you will need at higher doses now, while side effects are mild: protein at every meal, two or three resistance sessions weekly, a fiber source daily. Constipation prevention is much easier than constipation treatment.
Do not judge the medication on month one. 2.5 mg is a tolerance-building dose, not a treatment dose.
The end-of-month decision
Around week four your prescriber will discuss moving to 5 mg. Go if side effects are manageable. If they are not, ask to hold — an extra four weeks at 2.5 mg costs you very little and quitting costs you everything.
Common questions
Can I use HSA or FSA funds for tirzepatide?
Generally yes for prescribed weight-management medication, including compounded products, though some plan administrators require a letter of medical necessity. Confirm with your administrator and keep every receipt.
How long does it take to see results on tirzepatide?
Appetite change usually arrives within the first one to two weeks, often before the scale moves. Meaningful weight loss typically becomes visible between weeks 4 and 12, with the steepest part of the curve between months 3 and 9. Trial weight loss continued accumulating through week 72.
Does insurance cover tirzepatide?
It depends on your plan and your diagnosis. Many commercial plans exclude weight-management drugs entirely. Zepbound carries a specific FDA indication for moderate-to-severe obstructive sleep apnea with obesity, and plans that exclude weight loss often cover a diagnosed sleep disorder. With type 2 diabetes, Mounjaro is on-label.
What are the most common tirzepatide side effects?
Nausea (roughly 24–33%), diarrhea (19–23%), constipation (16–17%) and vomiting (8–12%). They cluster in the days after each dose increase and usually settle within one to two weeks at each new dose. Constipation is the one that most often persists.
People also ask about first 30 days tirzepatide
What is first 30 days tirzepatide?
First 30 days tirzepatide is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does first 30 days tirzepatide apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does first 30 days tirzepatide cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is first 30 days tirzepatide FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.